Why the study?
Does acetazolamide improve myotonia without causing weakness in patients with paramyotonia congenita?
Does acetazolamide improve myotonia without causing weakness in patients with paramyotonia congenita?
Low-dose acetazolamide can effectively treat myotonia in paramyotonia congenita without inducing the severe weakness previously reported with higher doses.
Answers are grounded in this paper and cite their sources.
May support low-dose acetazolamide in paramyotonia congenita; leaves open confirmation in controlled trials.
Treatment of paramyotonia congenita with acetazolamide has been shown to reduce myotonic symptoms but severe weakness has developed in some patients leading to a recommendation not to use the drug in this disorder. We studied a patient with the characteristic clinical and electrophysiological profile of paramyotonia congenita. Myotonia was effectively treated with a very low dose of acetazolamide and no weakness developed. We conclude that acetazolamide can be a safe and effective medication in paramyotonia congenita.
No takes yet. Share an insight, caveat, or question.
Benstead et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: